Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

canakinumab 180 MG Injection [Ilaris]

Known as: CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Ilaris], ILARIS 180 MG Injection 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic… Expand
Review
2015
Review
2015
Subcutaneous canakinumab (Ilaris®) is a human monoclonal anti-human interleukin (IL)-1β antibody of the immunoglobulin G1… Expand
  • table 1
  • table 2
  • table 3
Review
2013
Review
2013
Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a… Expand
  • table 1
  • figure 1
  • figure 2
Review
2013
Review
2013
Background There have been few published comparisons of various treatment options for acute gout flares that incorporate costs… Expand
2013
2013
Background Canakinumab (CAN, Ilaris®), a fully human anti-IL-1β monoclonal antibody, selectively inhibits IL-1β and has been… Expand